Gary W Pace insider trades: Cardiff Oncology (CRDF) stock buys and sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Gary reports to the SEC
and 1 more company
Open-market buys and sales
44 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Jul 14, 2026 | CRDF | ↑ Buy | 687,285 | $1.46 | $1000K | Direct | Jul 16, 2026 (2d) |
| Jun 18, 2026 | CRDF | ↑ Buy | 30,000 | $1.22 | $37K | Direct | Jun 22, 2026 (4d) |
| Jul 30, 2025 | CRDF | ↑ Buy | 275,000 | $2.45 | $674K | Direct | Jul 31, 2025 (1d) |
| Jul 30, 2025 | CRDF | ↑ Buy | 15,000 | $2.45 | $37K | By minor child | Jul 31, 2025 (1d) |
| Dec 11, 2024 | CRDF | ↑ Buy | 350,115 | $2.60 | $910K | Direct | Dec 12, 2024 (1d) |
| Dec 11, 2024 | CRDF | ↑ Buy | 11,500 | $2.60 | $30K | By minor child | Dec 12, 2024 (1d) |
| Mar 8, 2024 | PCRX | ↓ Sell | 119,323 | $30.64 | $3.7M | Direct | Mar 8, 2024 (0d) |
| Dec 19, 2023 | CRDF | ↑ Buy | 30,000 | $1.37 | $41K | Direct | Dec 19, 2023 (0d) |
| Nov 10, 2023 | CRDF | ↑ Buy | 22,950 | $0.98 | $22K | Direct | Nov 14, 2023 (4d) |
| May 11, 2023 | PCRX | ↓ Sell | 5,015 | $41.78 | $210K | Direct | May 15, 2023 (4d) |
| Sep 15, 2022 | CRDF | ↑ Buy | 150,000 | $1.71 | $257K | Direct | Sep 19, 2022 (4d) |
| Mar 1, 2022 | PCRX | ↓ Sell | 30,000 | $66.87 | $2.0M | Direct | Mar 1, 2022 (0d) |
| Sep 21, 2021 | CRDF | ↑ Buy | 30,000 | $6.75 | $203K | Direct | Sep 22, 2021 (1d) |
| Mar 23, 2021 | CRDF | ↑ Buy | 10,000 | $10.23 | $102K | Direct | Mar 24, 2021 (1d) |
| Mar 18, 2021 | CRDF | ↑ Buy | 3,000 | $10.55 | $32K | Direct | Mar 19, 2021 (1d) |
| Mar 4, 2021 | CRDF | ↑ Buy | 1,500 | $9.27 | $14K | Direct | Mar 4, 2021 (0d) |
| Sep 16, 2020 | CRDF | ↑ Buy | 2,550 | $5.70 | $15K | Direct | Sep 17, 2020 (1d) |
| May 11, 2020 | CRDF | ↑ Buy | 447,761 | $1.34 | $600K | Trust | May 13, 2020 (2d) |
| Nov 19, 2018 | PCRX | ↑ Buy | 4,500 | $46.18 | $208K | Direct | Nov 21, 2018 (2d) |
| Nov 7, 2018 | PCRX | ↑ Buy | 4,000 | $51.29 | $205K | Direct | Nov 9, 2018 (2d) |
| May 8, 2018 | RMD | ↓ Sell | 28,403 | $97.37 | $2.8M | Direct | May 10, 2018 (2d) |
| Jun 15, 2017 | RMD | ↓ Sell | 24,390 | $76.00 | $1.9M | Direct | Jun 16, 2017 (1d) |
| Aug 19, 2016 | RMD | ↓ Sell | 36,000 | $69.93 | $2.5M | Direct | Aug 22, 2016 (3d) |
| Mar 11, 2016 | RMD | ↓ Sell | 36,000 | $60.00 | $2.2M | Direct | Mar 14, 2016 (3d) |
| Mar 13, 2015 | PCRX | ↑ Buy | 1,000 | $93.83 | $94K | Direct | Mar 17, 2015 (4d) |
| Jan 26, 2015 | RMD | ↓ Sell | 48,000 | $66.77 | $3.2M | Pace Trust | Jan 28, 2015 (2d) |
| Aug 18, 2014 | RMD | ↓ Sell | 25,000 | $51.60 | $1.3M | Pace Trust | Aug 20, 2014 (2d) |
| Feb 18, 2014 | RMD | ↓ Sell | 48,000 | $46.06 | $2.2M | Direct | Feb 20, 2014 (2d) |
| Sep 9, 2013 | RMD | ↓ Sell | 12,000 | $50.05 | $601K | Direct | Sep 11, 2013 (2d) |
| Aug 7, 2012 | RMD | ↓ Sell | 48,000 | $36.00 | $1.7M | Direct | Aug 9, 2012 (2d) |
| Apr 17, 2012 | PCRX | ↑ Buy | 10,000 | $9.75 | $98K | Direct | Apr 17, 2012 (0d) |
| Jan 27, 2012 | RMD | ↓ Sell | 48,000 | $30.00 | $1.4M | Direct | Jan 31, 2012 (4d) |
| Nov 21, 2011 | PCRX | ↑ Buy | 7,692 | $6.50 | $50K | Direct | Nov 23, 2011 (2d) |
| Jun 22, 2011 | RMD | ↓ Sell | 64,000 | $31.16 | $2.0M | Direct | Jun 23, 2011 (1d) |
| Feb 19, 2010 | RMD | ↓ Sell | 32,000 | $57.21 | $1.8M | Direct | Feb 23, 2010 (4d) |
| May 11, 2009 | RMD | ↓ Sell | 10,666 | $39.95 | $426K | Direct | May 13, 2009 (2d) |
| Dec 4, 2008 | CLSN | ↑ Buy | 19,007 | $2.50 | $48K | Direct | Dec 5, 2008 (1d) |
| Dec 3, 2008 | PLI | ↑ Buy | 3,279 | $3.85 | $13K | Direct | Dec 4, 2008 (1d) |
| Dec 1, 2008 | PLI | ↑ Buy | 8,500 | $3.90 | $33K | Direct | Dec 2, 2008 (1d) |
| Feb 26, 2008 | CLN | ↑ Buy | 4,000 | $6.27 | $25K | Direct | Feb 27, 2008 (1d) |
| Feb 25, 2008 | CLN | ↑ Buy | 2,000 | $6.17 | $12K | Direct | Feb 27, 2008 (2d) |
| Mar 9, 2007 | RMD | ↓ Sell | 6,000 | $47.24 | $283K | Direct | Mar 12, 2007 (3d) |
| Mar 7, 2007 | RMD | ↓ Sell | 9,000 | $46.61 | $419K | Direct | Mar 8, 2007 (1d) |
| Aug 21, 2006 | RMD | ↓ Sell | 3,696 | $42.12 | $156K | Direct | Aug 25, 2006 (4d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other CRDF insiders
Open-market trades in the last 12 months
About Gary W Pace's insider trades
Gary W Pace is an insider at Cardiff Oncology (CRDF). Since Aug 21, 2006, Gary has reported 25 open-market purchases worth $4.8M and 19 sales worth $30.8M on SEC Form 4. In the last 12 months: 2 buys ($1.0M).
Their filings also include grants and awards (42 filings), option exercises (18 filings), other transactions (4 filings), gifts (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every CRDF insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.